CLINICAL_TRIALS
trial_result
· 2010-06-11
Clinical Trial Update: Pharmacokinetics and Pharmacodynamics of TAK-875 in Subjects With Type 2 Diabetes [Phase 1]
Summary
Phase 1 pharmacokinetic/pharmacodynamic evaluation of fasiglifam (TAK-875) in subjects with type 2 diabetes has been completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Takeda | Conditions: Diabetes Mellitus, Type 2 | Phase 1 | Status: COMPLETED